United Neuroscience is developing a novel class of vaccines that target aberrant proteins implicated in neurodegenerative diseases. Now it has strong preclinical evidence showing that one of its vaccines could hold promise in Parkinson’s disease.

SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) — Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that the first patient has been enrolled in its “VIVA” (Veinplicity for Improved Venous Access) Trial in the United States for the Veinplicity® Device.

GAITHERSBURG, Md., Nov. 12, 2018 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions.  “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage,” said Stanley Erck, President and Chief Executive Officer of Novavax, Inc. “These individuals have […]